Regulus Therapeutics Inc. (Nasdaq: RGLS) demonstrated human proof-of-concept
with a microRNA therapeutic for its hepatitis C treatment RG-101. Shares of the biopharmaceutical nearly doubled by jumping $6.63 to $13.40.
Regulus Therapeutics demonstrates human proof-of-concept
October 22, 2014 at 12:56 PM EDT